Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

SPRAVATO® Now Available at TMS Health and Wellness For Fast-Acting Relief of Treatment-Resistant Depression in Just Hours


News provided by

TMS Health and Wellness

Dec 26, 2022, 08:00 ET

Share this article

Share toX

Share this article

Share toX


Now treating major depressive disorder with FDA-approved nasal spray.

COSTA MESA, Calif., Dec. 26, 2022  /PRNewswire-PRWeb/ -- TMS Health and Wellness announced the launch of Spravato® (esketamine) as a supplemental in-clinic treatment approved for patients who have not received sufficient relief from antidepressants or even TMS therapy alone. Dr. Claudia Eppele's team at TMS Health and Wellness now provides the FDA-approved Spravato® as a nasal spray for patients who have tried oral antidepressants without the desired results. Spravato® is often approved for patients who have tried oral depressants for at least six to eight weeks without improvement of symptoms. For patients with continued depression, Spravato® can be an effective add-on treatment.

"We often see patients who have ongoing depression and do not respond well to oral antidepressants alone," says Dr. Claudia Eppele, M.D., founder and Chief Medical Officer at TMS Health and Wellness. "So, we're thrilled to provide Spravato® as a supplemental solution that can work rapidly for those with acute, debilitating depressive symptoms, or symptoms that may result in self-harm."

"We’re thrilled to provide Spravato® as a supplemental solution that can work rapidly for those with acute, debilitating depressive symptoms, or symptoms that may result in self-harm."

Post this

Eppele's team is now offering the life-changing therapeutic intervention, Spravato®, to clients at her Costa Mesa, California clinic. Spravato® was approved by the FDA in 2019 for use in adult patients with treatment-resistant depression and for the treatment of depressive symptoms in adults who have been diagnosed with major depressive disorder and who also suffer from suicidal thoughts or actions. Spravato® differs mechanistically from more traditional antidepressants. The exact method of action is unknown, but researchers believe Spravato® targets the N-methyl-D-aspartate (NMDA) receptor, which plays a role in mood.

While many oral antidepressants can take up to eight to 12 weeks to provide substantial improvements, Spravato® can offer near-immediate relief. Some patients experience improvements in symptoms within a matter of mere hours.

Spravato® is available in a nasal spray and is intended to be taken in conjunction with an oral antidepressant as a supplement to one's current depression treatment. Spravato® is only approved for in-clinic use, so patients cannot take the medication at home. This is because of the risk of side effects and the potential for substance abuse. Spravato® administration is available at healthcare clinics that have been specially certified through a Risk Evaluation and Mitigation Strategy (REMS), which is a restricted distribution system.

Spravato® is typically administered as a four-month course, with the treatment plan for Spravato® starting with two weekly sessions in the first month. The second month of treatment is one session a week. In the third month, treatment typically drops to just once every one or two weeks. Patients administer the nasal spray themselves under the close supervision of their provider, following a blood pressure evaluation. Patients remain at the clinic under observation so the provider can monitor possible side effects. During the observation period, providers periodically re-check the patient's blood pressure.

Spravato® is the latest non-traditional medical intervention offered by Eppele's team, specializing in its namesake, TMS, Transcranial Magnetic Stimulation. Each TMS treatment session includes many magnetic pulses. This treatment is typically prescribed after more standardized treatments, such as medications, or other forms of psychotherapy, have not delivered desirable results. The clinic continues to offer new ways for those who are battling depression, anxiety, addiction, OCD, tinnitus, traumatic brain injuries, chronic pain, or other neurological disorders to minimize their symptoms.

Dr. Epple has 11 years of experience in TMS, qualifying her as one of the first physicians on the west coast to utilize TMS therapy. She has given particular attention to evolving with the advancing technology by acquiring and mastering all of the most recent equipment for delivering the best TMS therapy possible. Experts can attest to the importance of choosing an experienced practitioner when it comes to TMS treatment, as only an advanced doctor can determine which TMS machines are appropriate for each patient within such as nuanced technological realm. To date, Dr. Eppele has successfully treated people dealing with OCD, tinnitus, Traumatic Brain Injury, chronic pain, strokes, migraine headaches, anxiety, and Bipolar Disorder, amongst other conditions. She incorporates hormonal testing and optimization when necessary, which have improved her efficacy rates. Her strategy combines her wealth of experience with compassion and precision care.

TMS Health and Wellness' unique approach to wellness enhances standard care by augmenting TMS and Spravato® therapies with various inner resource tools and natural remedies such as meditation, mindful self-compassion, natural medicine, and homeopathy. This supports the end treatment goal of offering non-drug alternative treatments that actually work. Spravato® is administered by prescription only under the supervision of a doctor while patients remain awake and alert.

Spravato® appointments are available now. For more information, visit the TMS Health and Wellness website.

Dr. Eppele can be made available for select in-person interviews with television news media in the Orange County, CA area and select Zoom interviews with media outlets worldwide to discuss the potential and benefits of Spravato® treatments.

About TMS Health and Wellness: Founded by Harvard-trained doctor, Claudia Eppele M.D., TMS Health and Wellness is one of the nation's premier Transcranial Magnetic Stimulation therapy centers. Practitioners use magnetic systems to impact the brain's mood center and provide results in as little as eight weeks. The clinic specializes in both iTBS and rTMS treatments and all other forms of non-invasive and natural therapies for depression and anxiety, including Spravato®.

Media Contact

Dr. Claudia Eppele, TMS Health and Wellness, 1 (855) 867-5551, [email protected]

Twitter

SOURCE TMS Health and Wellness

Modal title

Dr. Claudia Eppele, MD
Dr. Claudia Eppele, MD
Dr. Claudia Eppele, MD

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.